|| Checking for direct PDF access through Ovid
To evaluate the clinical value of Herbesser on the no-reflow in patients with acute coronary syndrome (ACS) under going percutaneous coronary intervention (PCI) Methods: January 2008–May 2014 in our hospital and underwent coronary angiography and drug-eluting stents (DES) implantation in more than 3,000 cases of ACS patients without intraoperative blood 60 cases, male 45 cases , 15 females, aged 35–75 years, mean age (56 ± 20) years old, were randomly divided into A, B groups (30 cases). A group of patients given intracoronary Herbesser 100–200 ug; Group B intraoperative given nitroprusside from coronary 100–200 ug, coronary blood flow was observed after administration of the recovery, cardiovascular events was observed after 30d incidence (the primary endpoint of cardiovascular death, revascularisation, target organs, malignant arrhythmia). The difference between the two groups was not statistically gender, age, severity of disease, complications, etc.: results. A group of intraoperative blood recovery TIMI3 grade 29 cases, TIMI2 flow grade one case, 30d after one case of malignant arrhythmias, angina two cases, no deaths, and target organ revascularisation; B group intraoperative blood recovery TIMI3 level 28 example, TIMI2 flow grade 2 cases, 1 case of malignant arrhythmias 30d, angina three cases, two blood flow is restored and the incidence of cardiovascular events was no statistical difference (p > 0.05).Herbesser and sodium nitroprusside in patients with acute coronary syndrome (ACS) interventional treatment can reduce the no flow phenomenon, so no blood flow is restored to the level TIMI2–3 blood flow, reduce the incidence of cardiovascular events.